doi: 10.1016/j.xcrm.2024.101919 180 KalkNJLingford-HughesAR
Eli Lillys orforglipron Phase III trial (ATTAIN-MAINTAIN) enabled injectable-to-oral transitions, preserving most weight loss over 52 weeks
Nhng ai nn s dng Ph n c nhu cu ci thin, chm sc v lm p da t su bn trong Ngi phi lm vic trong mi trng cng thng, thiu ng, thiu thi gian chm sc da Ngi c ln da cn c ci thin, ln da khng u mu, d ni mn, d gp phi cc tnh trng xu cho da Hng dn s dng vin ung trng da 2000mg Nu bn ang b NM nn: Ung 2 vin/ngy, vo bui sng v ti, trc n 30 pht hoc sau khi n 1 ting
Badania na modelach zwierzcych sugeruj, e peptyd moe wspiera neurogenez i napraw uszkodzonych tkanek mzgowych, co staje si priorytetem dla dalszych bada klinicznych
As a research tool, BPC-157 does not correspond to any known endogenous receptor ligand but has demonstrated interactions with several signaling systems in preclinical models
It means that the first step towards finding a DNA test for early-onset MVD genes has been taken